FONT-SIZE Plus   Neg

Peregrine Says Lung Cancer Trial Data Erroneous - Quick Facts

Peregrine Pharmaceuticals Inc. (PPHM) announced that during the course of preparing for an end-of-phase II meeting with regulatory authorities and following recent data announcements from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer, it discovered major discrepancies between some patient sample test results and patient treatment code assignments.

The company stated that due to the double-blind nature of the trial, it was not permitted to have access to either patient group assignments or related product coding information.

As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Schaeffler AG, the German auto parts maker owned by the Schaeffler family, Thursday set its initial public offering price at 12.50 euros per share. The company raised gross proceeds of about 938 million euros by offering 75 million shares, of which 66 million from Schaeffler AG and the remaining 9... Dick Costolo, who stepped down as CEO of Twitter in June, is taking a bit of a career turn - to Hollywood. The one-time tech darling left Twitter after 5 years at the helm amid Wall Street concerns about the future of the social media giant. Now he will be consulting on story lines for the HBO series Silicon Valley. Formula One is reportedly near a deal that would sell the racing circuit to an investor group that includes the owner of the Miami Dolphins. The Financial Times reports that the purchase price for the racing company is $8.5 billion. According to the paper, Dolphins owner Stephen Ross has reached a hand-shake agreement with CVC, a private equity firm holding a 35.5 percent stake in Formula One.
comments powered by Disqus
Follow RTT